The ARTERY FIRST Approach for Resection of Pancreatic Head Cancer

Status

UNKNOWN

Phases

Phase 3

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT01332773

Acronym

Artery first

Enrollment

124

Registered

2011-04-11

Start date

2010-03-31

Completion date

2011-07-31

Last updated

2011-04-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pancreatic Head Cancer

Brief summary

To show whether the artery first approach leads to equal or less rate of positive resection margins in pancreatic head cancer than the standard technique (ppWhipple only with standard Kocher's manoeuvre)

Detailed description

This is a prospective non-randomized trial with two study groups. The trial is designed to show if the ARTERY FIRST approach reduces the rate of R1 resections in patients undergoing surgery for cancer of the pancreatic head. After the diagnosis of cancer of the pancreatic head by clinical, laboratory and imaging evaluation patients who are scheduled for resection will be screened for inclusion into the trial. Informed consent is obtained at least on the day before surgery and patients meeting the eligibility criteria will be enrolled into the study.

Interventions

PROCEDUREArtery first procedure

early identification of SMA to evaluate infiltration

PROCEDURENo artery first procedure

conventional exposure and preparation (Kocher's manoeuvre) before transection of pancreatic parenchyma

Study design

Allocation

NON_RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Pancreatic head cancer (diagnosis by clinical, laboratory and radiological evaluation) * Patients scheduled for curative resection * No evidence of distant metastases * Age equal or greater than 18 years * Informed consent

Exclusion criteria

* Expected lack of compliance * Impaired mental state or language problems * patient having had neoadjuvant radiochemotherapy

Design outcomes

Primary

Measure	Time frame	Description
Rate of R1 resections	up to 1.5 years	positive resection margins as described by the pathologists of the University of Heidelberg

Secondary

Measure	Time frame	Description
Exploratory analyses	up to 1.5 years	Exploratory analyses of frequencies of complications and serious adverse events

Countries

Germany

Contacts

Primary ContactNuh N. Rahbari, MD

nuh.rahbari@med.uni-heidelberg.de+496221

Backup ContactHeike Elbers

heike.elbers@med.uni-heidelberg.de+496221

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026